Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.04B

Market cap28.04B

Price-Earnings ratio

21.52

Price-Earnings ratio21.52

Dividend yield

—

Dividend yield—

Average volume

1.00M

Average volume1.00M

High today

$192.28

High today$192.28

Low today

$185.36

Low today$185.36

Open price

$188.71

Open price$188.71

Volume

845.62K

Volume845.62K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$110.04

52 Week low$110.04

Stock Snapshot

Biogen(BIIB) stock is priced at $191.06, giving the company a market capitalization of 28.04B. It carries a P/E multiple of 21.52.

On 2026-03-26, Biogen(BIIB) stock moved within a range of $185.36 to $192.28. With shares now at $191.06, the stock is trading +3.1% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 845.62K, compared to an average daily volume of 1M.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

BIIB News

Nasdaq 14h

Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics

(RTTNews) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has e...

Simply Wall St 4d

Biogen Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential

Biogen (BIIB) is back in focus after Eisai and the company shared new real-world data at AD/PD 2026, showing that many patients remain on Alzheimer’s drug lecan...

TipRanks 4d

Biogen: Evolving Product Mix and Capital Discipline Position Shares for Revenue Reacceleration into 2027

Salveen Richter, an analyst from Goldman Sachs, maintained the Buy rating on Biogen. The associated price target remains the same with $231.00. Claim 30% Off Ti...

Analyst ratings

56%

of 36 ratings

Buy

41.7%

Hold

55.6%

Sell

2.8%

More BIIB News

Simply Wall St 6d

How Class Action Risks and Lupus Drug Advances Could Reframe Biogen's Innovation Narrative

Biogen recently saw a federal securities class action certified for investors who acquired its shares between June 8, 2021 and July 12, 2021, while also highlig...

TipRanks 6d

Biogen, Eisai report findings from analysis of long-term treatment with LEQEMBI

Eisai (ESAIY) and Biogen (BIIB) announced that new real-world findings from an analysis of long-term treatment persistence and baseline characteristics among pe...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.